摘要
目的:观察阿立哌唑合用文拉法辛缓释片治疗重症抑郁障碍的疗效和安全性。方法:将56例重症抑郁障碍患者随机分为两组各28例,分别用阿立哌唑合用文拉法辛缓释片及单用文拉法辛缓释片治疗,疗程8周。于治疗前及治疗后1、2、4、6、8周进行汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床疗效总评量表的病情严重程度(CGI-SI)、不良反应量表(TESS)评定。结果:治疗8周后两组HAMD、HAMA评分较治疗前低,差异有非常显著性(t=2.13,1.32,P<0.05);两组间2、6、8周HAMD评分及2、6周HAMA评分差异有显著性(t=2.03～3.00,P<0.05～0.01);观察组有效率82%,对照组有效率57%,差异有显著性(χ2=4.139,P<0.05);两组TESS评分差异有显著性(t=2.42,P<0.05)。结论:阿立哌唑合用文拉法辛缓释片治疗重症抑郁障碍疗效较好、安全性高。
Objective：To observe the efficacy and safety of Aripiprazole combined with Venlafaxine in the treatment of major depressive disorder.Methods：56 patients with major depression disorder were randomly divided into observation group（28 cases） and control group（28 cases）,Aripiprazole and Venlafaxine were used in observation group,and Venlafaxine was only used in control group,treatment for 8 weeks.All the patients were evaluated with HAMD,HAMA,clinical global impression scale（CGI-SI） and treatment emergent symptom scale（TESS） before treatment and at the end of 1st,2nd,4th,8th week.Results：Two groups of HAMD and HAMA score after 8 weeks of treatment than before treatment differences were significant（（t=2.13,1.32,P0.01）;the differences of HAMD scores of 2nd,6th,8th weeks and HAMA scores of 2nd,6th weeks between the two groups were significant（t=2.03~3.00,P0.05~0.01）;total clinical effective rate in observation group（82%） was significantly better than that in control group（57%）（χ2=4.139,P0.05）;Two groups of TESS score difference was significant（（t=2.42,P0.05）.Conclusion：Aripiprazole combined with Venlafaxine is effective and safe in the treatment of major depressive disorder.
出处
《中国民康医学》
2012年第6期655-656,664,共3页
Medical Journal of Chinese People’s Health
关键词
阿立哌唑
文拉法辛
重症抑郁障碍
Aripiprazole
Venlafaxine
Major depressive disorder
